OpenAlex
PricingAboutJobs
Log inGet started
Work

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

HTML

Year: 2015
Type: review
Source: Critical Reviews in Oncology/Hematology
DOI: 10.1016/j.critrevonc.2015.03.011
Authors: P.L. Zinzani, S. Sasse, J. Radford, O. Shonukan, V. Bonthapally
Institutions: University of Bologna, University Hospital Cologne, University of Manchester, The Christie NHS Foundation Trust, Takeda Oncology (United States)
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: brentuximab vedotin, relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, CD30, named patient program, real-world efficacy, drug safety, neurologic toxicity, hematologic toxicity, complete remission, pooled analysis
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2016561240
FWCI: 0.971
Cites: 21
Cited by: 33
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security